Jennifer A. Woyach

Professor and hematologist-oncologist, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center

Appears in 1 story

Last updated Oct 20, 2026

Stories

FDA approves Jaypirca for previously untreated CLL/SLL

New Capabilities

Active in CLL research and BTK inhibitor trials

The FDA on October 2 cleared Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, the first non-covalent BTK inhibitor approved as initial therapy. The label covers adults without a known 17p deletion, roughly 92% to 95% of new cases.

Updated Oct 20